Stockscreener 앱 받기
9.05
1.46%
0.13
시장 영업 전:
9.06
0.010
+0.11%
전일 마감가:
$8.92
열려 있는:
$8.9
하루 거래량:
138.00K
Relative Volume:
0.29
시가총액:
$167.68M
수익:
$1.54M
순이익/손실:
$-84.53M
주가수익비율:
-1.5565
EPS:
-5.8145
순현금흐름:
$-73.65M
1주 성능:
-2.90%
1개월 성능:
+0.78%
6개월 성능:
+9.43%
1년 성능:
-2.27%
1일 변동 폭
$8.79
$9.36
1주일 범위
$8.78
$9.54
52주 변동 폭
$7.12
$20.56
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
명칭
Corbus Pharmaceuticals Holdings Inc
전화
617-963-0103
주소
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP vs VRTX, REGN, ARGX, RVMD, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
9.05 | 168.23M | 1.54M | -84.53M | -73.65M | -5.8145 |
VRTX
Vertex Pharmaceuticals Inc
|
481.70 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
738.34 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
872.58 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
192.17 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
322.08 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-30 | 재개 | B. Riley Securities | Buy |
| 2025-02-28 | 개시 | William Blair | Outperform |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-07-30 | 개시 | Wedbush | Outperform |
| 2024-07-22 | 재개 | H.C. Wainwright | Buy |
| 2024-06-26 | 개시 | B. Riley Securities | Buy |
| 2024-06-03 | 재확인 | Oppenheimer | Outperform |
| 2024-05-13 | 개시 | RBC Capital Mkts | Outperform |
| 2024-03-06 | 업그레이드 | Jefferies | Hold → Buy |
| 2020-09-08 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2020-09-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-08 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-09-08 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-07-07 | 개시 | ROTH Capital | Buy |
| 2020-06-17 | 개시 | BTIG Research | Buy |
| 2020-03-26 | 개시 | Nomura | Buy |
| 2019-04-05 | 개시 | Jefferies | Buy |
| 2019-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-01-11 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-12-26 | 개시 | H.C. Wainwright | Buy |
| 2018-12-07 | 개시 | RBC Capital Mkts | Outperform |
| 2018-10-24 | 개시 | B. Riley FBR | Buy |
| 2018-01-19 | 개시 | Raymond James | Outperform |
| 2017-12-14 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-11-08 | 재확인 | Noble Financial | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-03-30 | 재확인 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | JMP Securities | Mkt Outperform |
| 2016-11-11 | 재확인 | Noble Financial | Buy |
모두보기
Corbus Pharmaceuticals Holdings Inc 주식(CRBP)의 최신 뉴스
Corbus Pharmaceuticals (CRBP) Gains FDA Nod for Pivotal CRB-701 - GuruFocus
Corbus Pharmaceuticals Holdings, Inc. initiates FDA-cleared registrational study for CRB-701 in oropharyngeal cancer - Traders Union
FDA clears Corbus registrational trial for head and neck cancer drug - Investing.com Canada
Corbus Pharmaceuticals Announces FDA Clearance to Initiate - GlobeNewswire
Corbus Pharmaceuticals Holdings Inc (CRBP) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
BlackRock, Inc. (CRBP) discloses 5.9% beneficial ownership in Corbus Pharmaceuticals - Stock Titan
Form 144 Corbus Pharmaceuticals Holdings For: 27 July By Investing.com - Investing.com Canada
Corbus Pharmaceuticals Holdings Inc - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CRBP|Corbus Pharmaceuticals Holdings Inc|Price:9.170|Chg%:-0.150 - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Cash Flow - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Corbus Pharmaceuticals Market Sentiment - Benzinga España
TradingKey - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Corbus Pharmaceuticals Holdings Inc (CRBP) Institutional Confidence - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors despite losses on the day - MarketWatch
Corbus Pharmaceuticals Holdings Inc (CRBP) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Corbus Pharmaceuticals Holdings Inc. stock outperforms competitors on strong trading day - MarketWatch
Corbus Pharmaceuticals stock steadies as pipeline advances after equity raise - Ad-hoc-news.de
Corbus Pharmaceuticals Holdings Inc. Stock Climbs 5.4%, Outperforms Peers - Bitget
(CRBP) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Corbus Pharmaceuticals Holdings Inc. stock rises Tuesday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Monday when compared to competitors - MarketWatch
Corbus Pharmaceuticals (CRBP) Q1 2026 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesHigh Growth Earnings - dars.gov.et
Corbus Pharmaceuticals (CRBP) Q1 2026 Earnings: Narrower-than-Expected Loss but Stock DeclinesEarnings Quality Analysis - dars.gov.et
Enterprise value to EBIT forward of Corbus Pharmaceuticals Holdings, Inc. – NASDAQ:CRBP - TradingView
Corbus Pharmaceuticals Holdings Inc. stock rises Thursday, still underperforms market - MarketWatch
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors despite daily gains - MarketWatch
symbol__ Stock Quote Price and Forecast - CNN
Corbus Pharmaceuticals (CRBP) Surges 4.22% as Shares Test Key ResistanceOvervalued Signals - dars.gov.et
Corbus Pharmaceuticals appoints Leonardo Viana Nicacio as chief medical officer - MSN
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio as Chief Medical Officer - citybiz
Corbus Pharmaceuticals Holdings, Inc. Announces Appointment of Leonardo Viana Nicacio as Chief Medical Officer - marketscreener.com
Corbus Pharmaceuticals names Leonardo Nicacio as CMO By Investing.com - Investing.com South Africa
Leonardo Viana Nicacio appointed as chief medical officer at Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharmaceuticals Appoints CMO Amid Key Trial Launches - TipRanks
Corbus Pharmaceuticals names Leonardo Nicacio as CMO - Investing.com
Corbus Pharmaceuticals (NASDAQ: CRBP) hires new CMO and details CRB-701, CRB-913 timelines - Stock Titan
Corbus Pharmaceuticals Appoints Leonardo Viana Nicacio, M.D. as Chief Medical Officer - The Manila Times
Corbus Pharmaceuticals outlines its immuno-oncology strategy as a clinical-stage biotech - Ad-hoc-news.de
Corbus Pharmaceuticals Holdings Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
CRBP issuer: affiliate Dominic Smethurst plans resale of 23,025 shares (CRBP) - Stock Titan
Corbus Pharmaceuticals Holdings Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
(CRBP) Risk Channels and Responsive Allocation - Stock Traders Daily
HPV positive oropharyngeal cancer strategy accelerates with new CRB-701 data at Corbus Pharmaceuticals Holdings, Inc. - Traders Union
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 2000 Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell 2000 Value Benchmark - marketscreener.com
CRBP Q1 2026 Earnings: EPS Beats Estimates Amid Pipeline ProgressAnalyst Consensus Shift - dars.gov.et
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM: CRBP) added to Russell 3000E Index - marketscreener.com
Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) added to Russell Small Cap Completeness Index - marketscreener.com
Corbus Pharmaceuticals Holdings Inc (CRBP) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Corbus Pharmaceuticals Holdings Inc 주식 (CRBP) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Kung Winston | Director |
Jun 10 '26 |
Sale |
7.91 |
2,026 |
16,033 |
12,140 |
| Altmeyer Anne | Director |
Jun 10 '26 |
Sale |
7.91 |
2,412 |
19,088 |
7,579 |
| Jenkins John Kenneth | Director |
Jun 10 '26 |
Sale |
7.91 |
4,800 |
37,986 |
3,833 |
| Saxena Nishant C | Chief Business Officer |
Jun 03 '26 |
Buy |
7.58 |
9,000 |
68,220 |
75,300 |
| Saxena Nishant C | Chief Business Officer |
Jun 02 '26 |
Buy |
7.33 |
4,500 |
32,998 |
66,300 |
| Smethurst Dominic | Chief Medical Officer |
Mar 02 '26 |
Sale |
8.30 |
6,097 |
50,601 |
89,790 |
0.11%
5.02%
자본화:
|
볼륨(24시간):